SYRE logo

Spyre Therapeutics Stock Price

Symbol: NasdaqGS:SYREMarket Cap: US$1.0bCategory: Pharmaceuticals & Biotech

SYRE Share Price Performance

SYRE Community Fair Values

    Recent SYRE News & Updates

    No updates

    Spyre Therapeutics, Inc. Key Details

    US$0

    Revenue

    US$169.5m

    Cost of Revenue

    -US$169.5m

    Gross Profit

    -US$10.2m

    Other Expenses

    -US$159.2m

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    -2.64
    Gross Margin
    0%
    Net Profit Margin
    0%
    Debt/Equity Ratio
    0%

    Spyre Therapeutics, Inc. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About SYRE

    Founded
    2013
    Employees
    73
    CEO
    Cameron Turtle
    WebsiteView website
    www.spyre.com

    Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

    U.S. Market Performance

    • 7 Days: -0.3%
    • 3 Months: 14.2%
    • 1 Year: 15.7%
    • Year to Date: 8.0%
    In the last week, the market has been flat, with a notable exception in the Materials sector dropping 4.1%. Meanwhile, the market is actually up 16% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
    Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
    Continue reading